中国神经再生研究(英文版) ›› 2017, Vol. 12 ›› Issue (11): 1870-1876.doi: 10.4103/1673-5374.219049

• 原著:退行性病与再生 • 上一篇    下一篇

毛蕊异黄酮激活蛋白激酶C通路改善阿尔茨海默病转基因小鼠的认知功能

  

  • 收稿日期:2017-10-14 出版日期:2017-11-15 发布日期:2017-11-15
  • 基金资助:

    中国博士后科学基金(801161020425);国家自然科学基金(8160010172)

Calycosin improves cognitive function in a transgenic mouse model of Alzheimer’s disease by activating the protein kinase C pathway

by Lei Song1, Xiaoping Li2, Xiao-xue Bai3, Jian Gao4, Chun-yan Wang3   

  1. 1 Department of Respiratory Medicine, First Hospital of Jilin University, Changchun, Jilin Province, China
    2 Department of Pediatrics, First Hospital of Jilin University, Changchun, Jilin Province, China
    3 Cadre’s Ward, First Hospital of Jilin University, Changchun, Jilin Province, China
    4 Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China
  • Received:2017-10-14 Online:2017-11-15 Published:2017-11-15
  • Contact: Chun-yan Wang, M.D., Ph.D.,cywangjlu@126.com
  • Supported by:

    This work was supported by the a grant from China Postdoctoral Science Project, No. 801161020425; and the Natural Science Foundation of China, No. 8160010172.

摘要:

阿尔茨海默病的主要病理改变为β淀粉样蛋白沉积,并伴随认知功能障碍。有研究表明传统中草药黄芪的主要生物活性化合物毛蕊异黄酮可减轻糖尿病所致的认知功能障碍,这也暗示其对阿尔茨海默病的认知功能可能具有改善作用。有研究显示蛋白激酶C是MAPK的上游通路,可通过调控与阿尔茨海默病有关的β淀粉样蛋白的降解起到神经保护作用。我们假设毛蕊异黄酮激活蛋白激酶C通路能够改善阿尔茨海默病转基因模型的认知功能。将不同剂量毛蕊异黄酮(10,20和40 mg/kg)腹腔注射于APP/PS1转基因阿尔茨海默病小鼠后发现,毛蕊异黄酮可呈剂量依赖性降低其海马β淀粉样蛋白,Tau蛋白,炎性因子白细胞介素1β和肿瘤坏死因子α,氧化应激标志物乙酰胆碱酯酶及丙二醛水平,并提高了乙酰胆碱水平及谷胱甘肽活性。给予蛋白激酶C抑制剂calphostin C可抵消毛蕊异黄酮改善APP/PS1小鼠认知能力、抗氧化和抗炎的神经保护作用。数据客观显示出了毛蕊异黄酮通过激活蛋白激酶C通路减轻阿尔茨海默病模型小鼠海马中氧化应激水平和炎症反应,从而改善阿尔茨海默病小鼠认知功能的作用。

orcid:0000-0002-2545-8128(Chun-yan Wang)

关键词: 神经再生, 神经退行性变, 阿尔茨海默病, 毛蕊异黄酮, 海马, 氧化应激, 炎症, 小鼠, 蛋白激酶C, calphostin C, 谷胱甘肽, 丙二醛

Abstract:

The major pathological changes in Alzheimer’s disease are beta amyloid deposits and cognitive impairment. Calycosin is a typical phytoestrogen derived from radix astragali that binds to estrogen receptors to produce estrogen-like effects. Radix astragali Calycosin has been shown to relieve cognitive impairment induced by diabetes mellitus, suggesting calycosin may improve the cognitive function of Alzheimer’s disease patients. The protein kinase C pathway is upstream of the mitogen-activated protein kinase pathway and exerts a neuroprotective effect by regulating Alzheimer’s disease-related beta amyloid degradation. We hypothesized that calycosin improves the cognitive function of a transgenic mouse model of Alzheimer’s disease by activating the protein kinase C pathway. Various doses of calycosin (10,20 and 40 mg/kg) were intraperitoneally injected into APP/PS1 transgenic mice that model Alzheimer’s disease. Calycosin diminished hippocampal beta amyloid, Tau protein, interleukin-1beta, tumor necrosis factor-alpha, acetylcholinesterase and malondialdehyde levels in a dose-dependent manner, and increased acetylcholine and glutathione activities. The administration of a protein kinase C inhibitor, calphostin C, abolished the neuroprotective effects of calycosin including improving cognitive ability, and anti-oxidative and anti-inflammatory effects. Our data demonstrated that calycosin mitigated oxidative stress and inflammatory responses in the hippocampus of Alzheimer’s disease model mice by activating the protein kinase C pathway, and thereby improving cognitive function.

Key words: nerve regeneration, neurodegeneration, Alzheimer’s disease, calycosin, hippocampus, oxidative stress, inflammation, mice, protein kinase C, calphostin C, glutathione, malondialdehyde, neural regeneration